Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6962843 | 0.80 | HTR1F (0.67) | HTR1FMAPTMAPKAPK2MEN1KMT2A | |
| Water SCHEMBL7653786 | 0.77 | HTR1F (0.65) | HTR1FMAPTMAPKAPK2RAB9A | |
| Formic Acid SCHEMBL8595097 | 0.74 | MAPKAPK2 (0.39) | HTR1FMAPTMAPKAPK2MEN1KMT2A | |
| SCHEMBL6957657 | 0.70 | HTR1F (0.67) | HTR1FMAPTMAPKAPK2MEN1KMT2A | |
| SCHEMBL7657208 | 0.68 | HTR1F (0.72) | HTR1FMAPTMEN1KMT2ARAB9A | |
| Formic Acid SCHEMBL6962862 | 0.68 | HTR1B (0.49) | HTR1FMAPTMEN1KMT2ARAB9A | |
| SCHEMBL6965234 | 0.67 | MAPKAPK2 (0.53) | MAPKAPK2RAB9A | |
| Water SCHEMBL7657950 | 0.67 | SMN1; SMN2 (0.52) | HTR1FMAPTMEN1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL6963197 | 0.67 | HTR1F (0.68) | HTR1FMAPTMAPKAPK2MEN1KMT2A | |
| SCHEMBL6959010 | 0.67 | HTR1F (0.65) | HTR1FMAPTMAPKAPK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0882726-B1 | Carbazol-carboxamides as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6221884-B1 | Carboxamides useful as 5-HT1F agonists | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| EP-0882726-A1 | Carbazol-carboxamides as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885MAPT 3544/4885MAPKAPK2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.